Eagle Bay Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-156
| Closed | -$5.64K | – | 847 |
|
|
2024
Q4 | $5.64K | Buy |
156
+7
| +5% | +$253 | ﹤0.01% | 682 |
|
|
2024
Q3 | $4.65K | Sell |
149
-80
| -35% | -$2.49K | ﹤0.01% | 1032 |
|
|
2024
Q2 | $6.13K | Sell |
229
-56
| -20% | -$1.5K | ﹤0.01% | 660 |
|
|
2024
Q1 | $9.72K | Sell |
285
-116
| -29% | -$3.96K | 0.01% | 592 |
|
|
2023
Q4 | $11.6K | Sell |
401
-2,811
| -88% | -$81.4K | 0.01% | 498 |
|
|
2023
Q3 | $88.6K | Buy |
3,212
+984
| +44% | +$27.1K | 0.04% | 275 |
|
|
2023
Q2 | $67K | Sell |
2,228
-572
| -20% | -$17.2K | 0.04% | 310 |
|
|
2023
Q1 | $101K | Sell |
2,800
-386
| -12% | -$14K | 0.06% | 233 |
|
|
2022
Q4 | $114K | Buy |
3,186
+515
| +19% | +$18.4K | 0.06% | 210 |
|
|
2022
Q3 | $91K | Buy |
2,671
+8
| +0.3% | +$273 | 0.06% | 214 |
|
|
2022
Q2 | $77K | Buy |
2,663
+1,567
| +143% | +$45.3K | 0.05% | 254 |
|
|
2022
Q1 | $35K | Sell |
1,096
-348
| -24% | -$11.1K | 0.03% | 182 |
|
|
2021
Q4 | $42K | Buy |
1,444
+750
| +108% | +$21.8K | 0.03% | 412 |
|
|
2021
Q3 | $18K | Sell |
694
-489
| -41% | -$12.7K | 0.01% | 615 |
|
|
2021
Q2 | $39K | Buy |
+1,183
| New | +$39K | 0.03% | 400 |
|